Epidermal growth factor receptor biology (IMC-C225)

Current Opinion in Oncology

Volumn 13, Issue 6, 2001, Pages 506-513

  Kim, Edward S ^a,b   Khuri, Fadlo R ^a   Herbst, Roy S ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Box 432 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CELL PROLIFERATION; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOLID TUMOR; TREATMENT PLANNING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DOWN-REGULATION; HUMANS; LIGANDS; NEOPLASMS; PROGNOSIS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0034754136     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200111000-00014     Document Type: Review

References (72)

1. Cell growth regulation in epithelial ovaria cancer
2. Quantitative estimation of epidermal growth factor receptor and c·erb·2 in human breast cancer
3. Amplification and overexpression of the epidermal growth factor receptor gene in human renal-cell carcinoma
4. Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma
5. Epidermal growth factor receptor ove expression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification
6. Expression of epidermal growth factor receptor in carcinoma of cervix
7. Gene amplification and overexpression of epidermal growth factor receptor in squamous cell carcinoma of the head and neck
8. Epidermal growth factor-related peptides and their receptors in human malignancies
9. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers
10. C-erbB2 amplification and overexpression in human tumors
11. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma
12. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms
13. EGFR and steroid receptors in ovarian carcinoma: Comparison with prognostic parameters and outcome of patients
14. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer
15. The relation of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival
16. Differential expression of epidermal growth factor receptor in human head and neck cancers
17. Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck
18. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in human squamous cell carcinoma HN5
19. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter
20. Prognostic applications of the epidermal growth factor receptor and its ligand, transforming growth factor-alpha
21. Prognostic value of epidermal growth factor receptor expression in cervical carcinoma
22. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival
23. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma
24. Epidermal growth factor
25. Modulation of molecular targets to enhance radiation
26. The epidermal growth factor receptor as a multifunctional allosteric protein
27. Epidermal growth factor-related peptides and their receptors in human malignancies
28. Growth factor receptor tyrosine kinases
29. Receptors for epidermal growth factor and other polypeptide mitogens
30. The EGF receptor: Structure, regulation and potential role in malignancy
31. Dysregulation of epidermal growth factor receptor expression in multistep process of head and neck tumorigenesis
32. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis
33. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells
34. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis
35. Chimeric monoclonal antibody (Mab) C225 to the epidermal growth factor receptor (EGF-R) antibody inhibits angiogenesis in human transitional cell carcinoma (TCC)
36. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
37. Biological modifiers as potential radiosensitizers: Targeting the epidermal growth factor receptor family
38. A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced tumor activities
39. Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response
40. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
41. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
42. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody
43. Anti-epidermal growth factor receptor monoclonal antibody C225 upregulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145
44. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin
45. Nuclear targeting of Bax during apoptosis in human colorectal cancer cells
46. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer do not involve the c·jun N·terminal kinase activity
47. Neutralizing antibodies against epidermal growth factor and ErbB·2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo
48. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics and tumor angiogenesis
49. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
50. Blockade of EGF-R signaling with anti-EGF-R monoclonal antibody (Mab) C225 inhibits matrix metalloproteinases-9 (MMP-9) expression and invasion of human transitional cell carcinoma (TCC) in vitro and in vivo
51. Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation
52. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy
53. Anti-tumor and cell responses in KB cells treated with a chimeric antiEGFR monoclonal antibody in combination with cisplatin
54. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts
55. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma
56. Altered cell cycle distribution and cyclin-CDK protein expression in A431 epidermoid carcinoma cells treated with doxorubicin and a chimeric monoclonal antibody to the epidermal growth factor receptor
57. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
58. Treatment of human tumor xenografts with a chimeric monoclonal antibody to the epidermal growth factor receptor in combination with Doxil, a novel liposomal form of doxorubicin
59. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
60. Potentiation of antitumor activity of PG-TXL with antiEGFR monoclonal antibody C225 in MDA-MB-468 human breast cancer xenograft
61. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of human pancreatic carcinoma xenograft in nude mice
62. Treatment of human intracranial gliomas with chimeric monoclonal antibody against the epidermal growth factor receptor increases survival of nude mice when treated concurrently with irradiation
63. Combined modality therapy of A431 human epidermoid cancer using antiEGFR antibody C225 and radiation
64. The biologic effects of anti-epidermal growth factor receptor and ionizing radiation in human head and neck tumor cell lines
65. In vivo enhancement of tumor radioresponse by C225 anti-epidermal growth factor receptor antibody
66. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: A new paradigm for cancer therapy
67. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
68. Epidermal growth factor receptor targeted therapy with humanized chimeric monoclonal antibody, C225 in combination with cisplatin in patients with head and neck cancer
69. Efficacy and safety of the anti-epidermal growth factor antibody (EGFR) IMC.C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy
70. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)
71. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer
72. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer